Dr. Margo R. Roberts Ph.D. serves as Independent Director of the Company. Dr. Roberts has served as Chief Scientific Officer of Lyell Immunopharma, Inc. Previously, Dr. Roberts served in multiple roles at Kite Pharma Inc., a public biopharmaceutical company acquired by Gilead in October 2017, including most recently as Senior Vice President of Discovery Research and Chief Scientific Officer from August 2011 to July 2018. Prior to that, Dr. Roberts served in multiple roles, including Principal Scientist and Director of Immune and Cell Therapy, at Cell Genesys, Inc., a biotechnology company, from January 1990 to December 1998. Dr. Roberts has also served as an associate professor at the University of Virginia from 1999 to 2011. Dr. Roberts is currently a member of board of Celyad SA, a public biotechnology and manufacturing services company, and InsTIL Bio Inc, a private biotechnology company focused on cellular manufacturing in oncology. Dr. Roberts received both her Bachelor of Science degree with honors and her Ph.D. degree from the University of Leeds in England. Roberts is qualified to serve on our board of directors because of her extensive experience in the biopharmaceutical industry.
As the Independent Director of Unity Biotechnology Inc, the total compensation of Margo Roberts at Unity Biotechnology Inc is $1,819,880. There are 1 executives at Unity Biotechnology Inc getting paid more, with Keith Leonard having the highest compensation of $3,270,820.
Margo Roberts is 65, he's been the Independent Director of Unity Biotechnology Inc since 2018. There are 1 older and 21 younger executives at Unity Biotechnology Inc. The oldest executive at Unity Biotechnology Inc is David Lacey, 67, who is the Independent Director.
Margo's mailing address filed with the SEC is C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 7 years, insiders at Unity Biotechnology Inc have traded over $9,012,473 worth of Unity Biotechnology Inc stock and bought 3,200 units worth $28,480 . The most active insiders traders include Kristina Burow, Robert Nelsen oraz Nathaniel E David. On average, Unity Biotechnology Inc executives and independent directors trade stock every 54 days with the average trade being worth of $65,316. The most recent stock trade was executed by Alexander Hieu Nguyen on 2 August 2024, trading 154 units of UBX stock currently worth $236.
unity biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. unity's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. more information is available at www.unitybiotechnology.com.
Unity Biotechnology Inc executives and other stock owners filed with the SEC include: